1,25-dyhydroxyvitamin D3 Attenuates l-DOPA-Induced Neurotoxicity in Neural Stem Cells

Molecular Neurobiology

Volumn 51, Issue 2, 2015, Pages 558-570

  Jang, Wooyoung ^a,b   Park, Hyun Hee ^a   Lee, Kyu Yong ^a   Lee, Young Joo ^a   Kim, Hee Tae ^a   Koh, Seong Ho ^a,c,d  

^a Hanyang University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Hanyang University   (South Korea)

^d Hanyang University Guri Hospital   (South Korea)

Author keywords

1,25 dyhydroxyvitamin D3; l DOPA; Neural stem cells; Neuroprotection

Indexed keywords

CALCITRIOL; LEVODOPA; NEUROPROTECTIVE AGENT;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; NEURAL STEM CELL; PHYSIOLOGY; RAT;

ANIMALS; CALCITRIOL; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; LEVODOPA; NEURAL STEM CELLS; NEUROPROTECTIVE AGENTS; RATS;

EID: 84939871929     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8835-1     Document Type: Article

References (61)

1. Jankovic J, Poewe W (2012) Therapies in Parkinson’s disease. Curr Opin Neurol 25(4):433–447
2. Katzenschlager R, Lees AJ (2002) Treatment of Parkinson’s disease: levodopa as the first choice. J Neurol 249(2):ii19–ii24
3. Schapira AHV, Olanow CW (2008) Drug selection and timing of initiation of treatment in early Parkinson’s disease. Ann Neurol 64(S2):S47–S55
4. Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 252(4):iv37–iv42
5. Lipski J, Nistico R, Berretta N, Guatteo E, Bernardi G, Mercuri NB (2011) l-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson’s disease? Prog Neurobiol 94(4):389–407
6. Müller T, Hefter H, Hueber R, Jost W, Leenders K, Odin P, Schwarz J (2004) Is levodopa toxic? J Neurol 251(6):vi44–vi46
7. Parkkinen L, O’Sullivan SS, Kuoppamäki M, Collins C, Kallis C, Holton JL, Williams DR, Revesz T, Lees AJ (2011) Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 77(15):1420–1426
8. Agil A, Durán R, Barrero F, Morales B, Araúzo M, Alba F, Miranda MT, Prieto I, Ramírez M, Vives F (2006) Plasma lipid peroxidation in sporadic Parkinson’s disease. Role of the l-dopa. J Neurol Sci 240(1–2):31–36
9. Chen J, Wersinger C, Sidhu A (2003) Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity. J Biol Chem 278(30):28089–28100
10. Maharaj H, Sukhdev Maharaj D, Scheepers M, Mokokong R, Daya S (2005) l-DOPA administration enhances 6-hydroxydopamine generation. Brain Res 1063(2):180–186
11. Soliman MK, Mazzio E, Soliman KFA (2002) Levodopa modulating effects of inducible nitric oxide synthase and reactive oxygen species in glioma cells. Life Sci 72(2):185–198
12. Koshimura K, Tanaka J, Murakami Y, Kato Y (2000) Effects of dopamine and L-DOPA on survival of PC12 cells. J Neurosci Res 62(1):112–119
13. Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW (2003) Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 304(2):792–800
14. Shin JY, Park H-J, Ahn YH, Lee PH (2009) Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson’s disease: a direct comparison study. J Neurochem 111(4):1042–1050
15. Olanow CW, Obeso JA (2011) Levodopa toxicity and Parkinson disease: still a need for equipoise. Neurology 77(15):1416–1417
16. Arias-Carrión O, Yamada E, Freundlieb N, Djufri M, Maurer L, Hermanns G, Ipach B, Chiu W-H, Steiner C, Oertel W, Höglinger G (2009) Neurogenesis in substantia nigra of parkinsonian brains? In: Giovanni G, Di Matteo V, Esposito E (eds) Birth, life and death of dopaminergic neurons in the substantia nigra, vol 73. J Neural Transm. Supplementa. Springer Vienna, pp 279–285
17. Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC (2004) Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7(7):726–735
18. Yoshimi K, Ren Y-R, Seki T, Yamada M, Ooizumi H, Onodera M, Saito Y, Murayama S, Okano H, Mizuno Y, Mochizuki H (2005) Possibility for neurogenesis in substantia nigra of parkinsonian brain. Ann Neurol 58(1):31–40
19. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen E-Y, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Déglon N, Aebischer P (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 290(5492):767–773
20. Lie DC, Dziewczapolski G, Willhoite AR, Kaspar BK, Shults CW, Gage FH (2002) The adult substantia nigra contains progenitor cells with neurogenic potential. The Journal of Neuroscience 22(15):6639–6649
21. Parain K, Murer MG, Yan Q, Faucheux B, Agid Y, Hirsch E, Raisman-Vozari R (1999) Reduced expression of brain-derived neurotrophic factor protein in Parkinson’s disease substantia nigra. NeuroReport 10(3):557–561
22. Zhu Q, Ma J, Yu L, Yuan C (2009) Grafted neural stem cells migrate to substantia nigra and improve behavior in Parkinsonian rats. Neurosci Lett 462(3):213–218
23. Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Saaksjarvi K, Heliovaara M (2010) Serum vitamin D and the risk of Parkinson disease. Arch Neurol 67(7):808–811
24. Newmark HL, Newmark J (2007) Vitamin D and Parkinson’s disease—a hypothesis. Mov Disord 22(4):461–468
25. Shinpo K, Kikuchi S, Sasaki H, Moriwaka F, Tashiro K (2000) Effect of 1,25-dihydroxyvitamin D3 on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L-buthionine sulfoximine and 1-methyl-4-phenylpyridine. J Neurosci Res 62(3):374–382
26. Taniura H, Ito M, Sanada N, Kuramoto N, Ohno Y, Nakamichi N, Yoneda Y (2006) Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J Neurosci Res 83(7):1179–1189
27. Wang J-Y, Wu J-N, Cherng T-L, Hoffer BJ, Chen H-H, Borlongan CV, Wang Y (2001) Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res 904(1):67–75
28. Bae EJ, Lee HS, Park CH, Lee SH (2009) Orphan nuclear receptor Nurr1 induces neuron differentiation from embryonic cortical precursor cells via an extrinsic paracrine mechanism. FEBS Lett 583(9):1505–1510
29. Chang M-Y, Son H, Lee Y-S, Lee S-H (2003) Neurons and astrocytes secrete factors that cause stem cells to differentiate into neurons and astrocytes, respectively. Mol Cell Neurosci 23(3):414–426
30. Kim J-Y, Koh HC, Lee J-Y, Chang M-Y, Kim Y-C, Chung H-Y, Son H, Lee Y-S, Studer L, McKay R, Lee S-H (2003) Dopaminergic neuronal differentiation from rat embryonic neural precursors by Nurr1 overexpression. J Neurochem 85(6):1443–1454
31. Jiang Q, Gu Z, Zhang G, Jing G (2000) Diphosphorylation and involvement of extracellular signal-regulated kinases (ERK1/2) in glutamate-induced apoptotic-like death in cultured rat cortical neurons. Brain Res 857(1–2):71–77
32. Koh S-H, Song C, Noh MY, Kim HY, Lee K-Y, Lee YJ, Kim J, Kim SH, Kim H-T (2008) Inhibition of glycogen synthase kinase-3 reduces l-DOPA-induced neurotoxicity. Toxicology 247(2–3):112–118
33. Lee YJ, Park KH, Park H-H, Kim YJ, Lee K-Y, Kim SH, Koh S-H (2009) Cilnidipine mediates a neuroprotective effect by scavenging free radicals and activating the phosphatidylinositol 3-kinase pathway. J Neurochem 111(1):90–100
34. Fukuda S, Kato F, Tozuka Y, Yamaguchi M, Miyamoto Y, Hisatsune T (2003) Two distinct subpopulations of nestin-positive cells in adult mouse dentate gyrus. J Neurosci 23(28):9357–9366
35. Kay JN, Blum M (2000) Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection. Dev Neurosci 22(1–2):56–67
36. Lazarov O, Marr R (2010) Neurogenesis and Alzheimer’s disease: at the crossroads. Exp Neurol 223:267–281
37. Steiner B, Wolf S, Kempermann G (2006) Adult neurogenesis and neurodegenerative disease. Regen Med 1(1):15–28
38. Politis M, Lindvall O (2012) Clinical application of stem cell therapy in Parkinson’s disease. BMC Med 10(1):1
39. Gerlach M, Braak H, Hartmann A, Jost WH, Odin P, Priller J, Schwarz J (2002) Current state of stem cell research for the treatment of Parkinson’s disease. J Neurol 249(3):iii33–ii35
40. Lindvall O, Björklund A (2011) Cell therapeutics in Parkinson’s disease. Neurotherapeutics 8(4):539–548
41. Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V (2011) High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol 68(3):314–319
42. Burne THJ, McGrath JJ, Eyles DW, Mackay-Sim A (2005) Behavioural characterization of vitamin D receptor knockout mice. Behav Brain Res 157(2):299–308
43. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ (2005) Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. J Chem Neuroanat 29(1):21–30
44. Koh S-H, Park H-H, Choi N-Y, Lee K-Y, Kim S, Lee YJ, Kim H-T (2011) Protective effects of statins on l-DOPA neurotoxicity due to the activation of phosphatidylinositol 3-kinase and free radical scavenging in PC12 cell culture. Brain Res 1370:53–63
45. Park H-H, Lee K-Y, Kim SH, Lee YJ, Koh S-H (2009) l-DOPA-induced neurotoxicity is reduced by the activation of the PI3K signaling pathway. Toxicology 265(3):80–86
46. Nyholm D, Lennernäs H, Gomes-Trolin C, Aquilonius S-M (2002) Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson’s disease on individual drug combinations. Clin Neuropharmacol 25(2):89–96
47. Brewer LD, Thibault V, Chen K-C, Langub MC, Landfield PW, Porter NM (2001) Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 21(1):98–108
48. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D (2002) New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab TEM 13(3):100–105
49. Liu W-G, Chen Y, Li B, Lu G-Q, Chen S-D (2004) Neuroprotection by pergolide against levodopa-induced cytotoxicity of neural stem cells. Neurochem Res 29(12):2207–2214
50. Kriebitzsch C, Verlinden L, Eelen G, van Schoor NM, Swart K, Lips P, Meyer MB, Pike JW, Boonen S, Carlberg C, Vitvitsky V, Bouillon R, Banerjee R, Verstuyf A (2011) 1,25-dihydroxyvitamin D3 influences cellular homocysteine levels in murine preosteoblastic MC3T3-E1 cells by direct regulation of cystathionine β-synthase. J Bone Miner Res 26(12):2991–3000
51. Prufer K, Jirikowski GF (1997) 1.25-Dihydroxyvitamin D3 receptor is partly colocalized with oxytocin immunoreactivity in neurons of the male rat hypothalamus. Cell Mol Biol 43(4):543–548
52. Sutherland MK, Somerville MJ, Yoong LK, Bergeron C, Haussler MR, McLachlan DR (1992) Reduction of vitamin D hormone receptor mRNA levels in Alzheimer compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels. Brain Res Mol Brain Res 13(3):239–250
53. Hall A, Juckett M (2013) The role of vitamin D in hematologic disease and stem cell transplantation. Nutrients 5(6):2206–2221
54. Samuel S, Sitrin MD (2008) Vitamin D’s role in cell proliferation and differentiation. Nutr Rev 66:S116–S124
55. Klotz B, Mentrup B, Regensburger M, Zeck S, Schneidereit J, Schupp N, Linden C, Merz C, Ebert R, Jakob F (2012) 1,25-dihydroxyvitamin D3 treatment delays cellular aging in human mesenchymal stem cells while maintaining their multipotent capacity. PLoS One 7(1):e29959
56. Höhler B, Lange B, Holzapfel B, Goldenberg A, Hänze J, Sell A, Testan H, Möller W, Kummer W (1999) Hypoxic upregulation of tyrosine hydroxylase gene expression is paralleled, but not induced, by increased generation of reactive oxygen species in PC12 cells. FEBS Lett 457(1):53–56
57. Kastner A, Herrero MT, Hirsch EC, Guillen J, Luquin MR, Javoy-Agid F, Obeso JA, Agid Y (1994) Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy. Ann Neurol 36(2):206–214
58. Walkinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson’s disease. J Clin Invest 95(6):2458–2464
59. Nakao N, Nakai K, Itakura T (1997) Metabolic inhibition enhances selective toxicity of l-DOPA toward mesencephalic dopamine neurons in vitro. Brain Res 777(1–2):202–209
60. de Groot MWGDM, Westerink RHS Chemically-induced oxidative stress increases the vulnerability of PC12 cells to rotenone-induced toxicity. NeuroToxicology (0)
61. Peritore CS, Ho A, Yamamoto BK, Schaus SE (2012) Resveratrol attenuates L-DOPA-induced hydrogen peroxide toxicity in neuronal cells. NeuroReport 23(17):989–994